Milestone Merger Payment made with Predictive Oncology to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond: Renovaro, Inc. (NASDAQ: RENB)
$RENB Secures $15 Million in New Equity to Support Operations Towards Revolutionizing Healthcare with $POAI
• Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery.
• Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).
• $15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies.
• 2025 Shareholder Update Issued from CEO.
• Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025.
• Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI.
• Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.
• Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.
Renovaro, Inc. (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
First Milestone Payment to Finalize Agreement with Predictive Oncology to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States
On March 3rd RENB announced it has advanced the first tranche of financing to) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States.
By adding Predictive's AI-driven drug discovery platform, vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data to the RENB multi-disciplinary artificial intelligence, multi-omic and multi-modal data expertise, the combined company will be positioned to commercialize its drug discovery and diagnostic platforms.
On February 26th RENB announced its definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas.
At the core of this collaboration is BioSymetrics' proprietary Elion platform, a cutting-edge AI and machine learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics' Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics' advanced AI in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling BioSymetrics has amassed an incredible database of proprietary in vivo experimentation, with associated behavioral and morphological analysis. This integrated approach hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into the RENB workflow, the combined entity aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.
BioSymetrics' AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, RENB will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.
For more information on BioSymetrics visit: www.biosymetrics.com.
$15 Million in New Equity Committed
RENB has also announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
David Weinstein, Chief Executive Officer of Renovaro, commented, 'We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.'
Shareholder Letter and Corporate Update
On January 7th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary:
RENB recently signed a binding letter of intent to acquire Predictive Oncology (NASDAQ: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs.
When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines. There are two business developments that RENB is pursuing.
Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform.
GEDiCube to deploy its AI/ML analysis to discover more genes and factors that can be deployed in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for our DCCV and generate business development RENB will be attending the American Association for Cancer Research (AACR), the first and largest cancer research organization, Annual Meeting in April 2025.
To make its AI/ML powered early cancer detection tests a reality, RENB requires two vital components: the latest superpods to achieve the speed necessary to run trillions of calculations, and critical data and sample sets. RENB announced in late December 2024, a strategic collaboration with Nebul (www.nebul.com) that will provide that power. Additionally, Nebul is focused on healthcare and is ISO certified. The company has received a grant for the Lumina project that aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for non-small cell lung cancer (NSCLC). This project provides RENB with 100 samples for immediate analysis followed by an additional 200 samples as they are generated and provides critical data.
For more information on $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Disclosure listed on the CorporateAds website
Media Contact
Company Name: Renovaro Inc.
Contact Person: David Weinstein, CEO
Email: Send Email
Phone: 732-780-5036
Address: 2080 Century Park East Suite 906
City: Los Angeles
State: California
Country: United States
Website: www.renovarobio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
2 Social Media Stocks That Are Screaming Buys in June
After a rough start to the year, tech stocks have come roaring back. As of this writing, the tech-heavy Nasdaq Composite index has surged by more than 25% over the last two months. So with market sentiment swinging back in favor of tech stocks, let's have a closer look at two social media stocks that I believe are buys right now. Reddit First up is Reddit (NYSE: RDDT). A relative newcomer as far as social media stocks go, Reddit has only been a public company for a little over a year. However, during that time, its shares have soared by more than 250%. What's behind that excellent performance? In short, red-hot growth across the board. For the first quarter, Reddit delivered a stunning report. Highlights included: Explosive revenue growth of 61% year over year International revenue growth of 82% Average revenue per user (ARPU) 23% higher than a year earlier Daily average users (DAUs) 31% higher Gross margin now 90.5%, compared to 88.6% a year ago Net income of $26 million versus a loss of $575 million last year Reddit, which hosts hundreds of thousands of "subreddits," is part of the growing internet ecosystem that includes large language models (LLMs) like ChatGPT, search engines like Alphabet 's Google, and social media networks. Since Reddit's users create millions of pieces of unique content and post subjective opinions on current events, the platform plays a key role in shaping search results and responses from LLMs. In addition, the company has gotten into the LLM game with its Reddit Answers feature, which boasts over 1 million weekly average users (WAUs). Here's the key takeaway: Reddit is an up-and-coming social media stock with a still-modest market cap of $22 billion. Its volatility and meager (for now) profits mean the stock isn't a great fit for everyone, particularly value investors. However, for long-term-oriented growth investors, Reddit is a name to consider in June. Meta Platforms Then, there's Meta Platforms (NASDAQ: META). What I love about Meta's stock performance is that the company makes it look easy. Consider its latest earnings report. In the first quarter, the company posted: $42 billion in revenue $17 billion in net income $10 billion in free cash flow Bear in mind that those are figures for a single quarter. On a yearly basis, the company is on track to generate nearly $190 billion in revenue, meaning its total revenue this year could match -- or perhaps surpass -- iconic American companies like Ford Motor Company, General Motors, and Chevron. META Annual Revenue Estimates data by YCharts. In addition to its excellent results, the company is also making moves for the future. Meta is spending heavily on artificial intelligence (AI) infrastructure, such as AI chips and data centers. Those investments are intended to upend the advertising landscape -- and put Meta at the heart of the digital advertising ecosystem. By 2026, the company wants to fully automate ads, allowing brands to cut out advertising-agency intermediaries altogether. What's more, Meta wants to automate the process using AI, allowing brands to customize their ads based on the viewer's location and tastes. In other words, Meta is aiming for another big leap forward -- one that could deliver another surge in revenue, profits, and free cash flow. For investors, now could be the time to load up on Meta shares, before the company begins to reap the rewards of its AI investments. However, given how far Meta has already climbed this year (at this writing, the stock is up 19% year to date), a dollar-cost-averaging strategy could be a savvy way to build a long-term position. Should you invest $1,000 in Meta Platforms right now? Before you buy stock in Meta Platforms, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Meta Platforms wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors.
Globe and Mail
2 hours ago
- Globe and Mail
Here's How Investing $300 Per Month Can Create $50,000 in Annual Dividends
Being able to live off dividend income in your retirement years can be a great goal to aim for. And by investing in the stock market, growing your portfolio, and investing in dividend-paying stocks, that can be possible. But just how does that all work? Below, I'll outline a strategy that can help you build up a strong portfolio balance over time through monthly investments of $300, and then, how that can eventually be transformed into a portfolio that's generating around $50,000 per year in dividends for you. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Investing in a growth-focused fund can build up a strong portfolio balance in the long term To achieve the best returns over the long run, you'll likely want to have a position in top growth stocks. While they can be volatile, especially in the short term, over a long period of time, you should benefit from their growth and rising valuations. It can, however, be hard to pick the right growth stocks and determine the right mix of them. In order to get around this, you can simply invest in the Invesco QQQ Trust (NASDAQ: QQQ). The exchange-traded fund (ETF) will give you exposure to the top 100 non-financial stocks on the Nasdaq Stock Exchange. There's no worry about having to change your portfolio composition over the years and determining which stocks to buy and sell. All that is taken care of for you through this ETF, which does the work for you. Over the past decade, the QQQ ETF has easily beaten the S&P 500, and is a great example of why it can be an ideal investment option when pursuing long-term growth. Data by YCharts. Historically, the S&P 500 has averaged an annual total return of close to 10%. It's possible that slower annual returns may be on the horizon, given how strong the market has been in recent years. But for the Invesco QQQ Trust, which has performed much better than the market, a 10% total annual return would be a slowdown, and thus, may be a realistic percentage to use when forecasting its future performance. If you were to invest $300 per month into the fund, and it ended up averaging a 10% annual total return (compounded), then after 35 years, your portfolio balance could climb to a value of over $1.1 million. Once you have a high enough balance, dividend stocks can do the rest With $1.1 million, you would need to put that money into investments that yield a little more than 4.5% to generate dividend income of $50,000 per year. If your balance is not at such a high level, then you would need to target a higher yield for that to be possible, and that can result in taking on a bit too much risk. After building up your portfolio to such a large amount, it'll be important to balance both dividend income along with capital preservation; you don't want all that work of growing your portfolio to go to waste by gambling it on a risky dividend. In 35-plus years, there will be new income-generating investments to consider, but one example today of an ETF that could bring in a lot of income is the iShares International Select Dividend ETF (NYSEMKT: IDV), which yields 5.3% and gives you exposure to international companies from all over the world. This or a similar type of investment could help provide you with a sufficiently high yield to produce $50,000 in annual dividends on a $1.1 million balance, while keeping your risk relatively low. Another thing you can do to try to minimize your risk is to spread your total investment across multiple ETFs. As long as you're averaging around 4.5%, then the end result can still be the same: $50,000 in dividends per year. Investing regularly into stocks is a good move for the long run Regardless of what the outlook may be for the stock market this year, or for the next few years, routinely investing in it can still be an effective way of building up your wealth over the long haul. Timing the market is a risky strategy that can result in you missing out on gains. By simply making it a routine to invest in a fund like the Invesco QQQ Trust each month, you don't need to worry about external factors -- simply trust the process. There may be anxiety and poor returns in any one year, but the long-term trajectory is still likely to be a very strong and positive one. Should you invest $1,000 in Invesco QQQ Trust right now? Before you buy stock in Invesco QQQ Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.
Globe and Mail
3 hours ago
- Globe and Mail
Better Hypergrowth Stock: Rigetti Computing vs. CoreWeave
Rigetti Computing (NASDAQ: RGTI) and CoreWeave (NASDAQ: CRWV) both look like exciting growth plays for investors who can tolerate a lot of risk. Rigetti is an early mover in the quantum computing market, and CoreWeave is one of the market's fastest-growing artificial intelligence (AI) companies. Over the past 12 months, Rigetti's stock gained more than 970%. CoreWeave, which went public in March, has already soared about 250% from its IPO price of $40. Should you chase either of these high-flying hypergrowth tech stocks today? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Rigetti's nascent business has room to grow Rigetti provides quantum processing units (QPUs), full quantum systems, and a cloud-based platform for developing quantum applications. That makes it a one-stop shop for quantum computing solutions, and it has been expanding its menu of offerings with cheaper commercial systems and modular systems that link together multiple systems. Classical computers store and process data in binary bits: zeros and ones. Quantum computers use a different paradigm that takes advantage of the peculiarities of quantum mechanics: They use qubits, which can be ones or zeroes, but can also have values that are probability amplitudes -- complex weighted combinations of those zero and one states. As an investor, you don't need to understand how it works: What matters is that using qubits to process calculations allows quantum computers to quickly get answers to some unusual types of problems that would take years or even centuries for classical supercomputers to solve. The downsides are that quantum computers are bigger, pricier, and consume much more power. Also, because qubits are finicky and fragile, outside interference can flip their states. As a result, today's quantum computers produce errors once every few hundred operations, vastly more often than traditional computers, whose ratios are measured in errors per billion or trillion operations. To make quantum computing technology truly useful, its error rates will have to come down to magnitudes of one in a million or better. Rigetti's big customers include the Superconducting Quantum Materials and Systems Center, the Air Force Research Lab, and the Horizon Quantum Computing in Singapore. Its recent product launches include its smaller 9-qubit Novera QPU for commercial customers and its 84-qubit Ankaa 3 quantum system for government and research clients. It plans to launch a new modular system, which connects four of its 9-qubit systems to create a 36-qubit system, later this year. It aims to launch a non-modular 100-qubit system in 2026. Rigetti's revenue declined by 8% in 2023 and another 10% in 2024, mainly due to its lack of new R&D milestone payments and the uneven timing of payments from its government and research contracts. The company's net loss also widened from $75 million in 2023 to $201 million in 2024. But from 2024 to 2027, analysts expect its revenue to grow at a compound annual rate of 52% from $10.8 million to $37.7 million, and expect it to narrow its net loss to $85.4 million. That acceleration should be driven by more commercial contracts and even more powerful systems. But with a market cap of $3.3 billion currently, Rigetti already trades at 87 times its estimated sales for 2027. It might eventually grow into that valuation if it scales up its business and its quantum systems become more widely adopted for mainstream computing applications, but that valuation bubble could also burst if it fails to meet Wall Street's high expectations. That might be why company insiders sold five times as many shares as they bought over the past 12 months. CoreWeave has carved out a high-growth AI niche CoreWeave was founded as an Ethereum -mining business in 2017, but it abandoned that market after the cryptocurrency crash of 2018. The company then repurposed its crypto-mining GPUs (graphics processing units) to power AI tasks on its new cloud infrastructure platform, which it significantly expanded with a $100 million purchase of Nvidia 's H100 GPUs in 2022. CoreWeave then leveraged its GPUs as collateral to secure even more funding, and it attracted some big investments from Nvidia, Cisco, and PureStorage. That support helped the company expand from just three AI data centers at the end of 2022 to 33 such locations across the U.S. and Europe today. It claims its dedicated GPU approach makes it roughly 35 times faster and 80% cheaper for tackling AI tasks than traditional cloud platforms, and its top customers already include AI leaders like Microsoft and OpenAI. As CoreWeave opened more data centers to meet the growing demand in the AI space, its revenue surged from $16 million in 2022 to $1.92 billion in 2024. However, its net loss widened from $31 million in 2022 to $863 million in 2024 as it bought and leased more data centers, bought more GPUs from Nvidia, and dealt with higher energy costs. From 2024 to 2027, analysts expect CoreWeave's revenue to soar at a compound annual rate of 105% to $16.55 billion, and expect it to narrow its net loss to $747 million. That's an impressive growth trajectory, but soaring expenses and high debt could throttle long-term expansion. It could also face fresh competition as bigger cloud platforms roll out more dedicated AI services. With a market cap of $67.3 billion, CoreWeave seems more reasonably valued than Rigetti at 4 times its estimated sales for 2027. But when its lockup period expires on Sept. 24, a lot of its insiders could rush to sell and take profits on the high-flying stock. The better hypergrowth play: CoreWeave Rigetti might have a bright future as the quantum computing market expands, but its business is still wobbly and it is trading at meme stock valuations. CoreWeave is also risky, but it's growing faster and its valuations look more reasonable. So if I could only pick one of these hypergrowth stocks today, I'd choose CoreWeave. Should you invest $1,000 in Rigetti Computing right now? Before you buy stock in Rigetti Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rigetti Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cisco Systems, Ethereum, Microsoft, Nvidia, and Pure Storage. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
